Next Article in Journal
Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Next Article in Special Issue
Mutual Balance between Vasohibin-1 and Soluble VEGFR-1 in Endothelial Cells
Previous Article in Journal
Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
Previous Article in Special Issue
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action
Open AccessReview

Endogenous Matrix-Derived Inhibitors of Angiogenesis

Department of Surgery, Umea University Hospital, Umea University, SE-90185 Umea, Sweden
Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland
Department of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, Bergen, Norway
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(10), 3021-3039;
Received: 10 August 2010 / Revised: 19 September 2010 / Accepted: 25 September 2010 / Published: 28 September 2010
(This article belongs to the Special Issue Angiogenesis Inhibitors)
Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM) surrounding cells. Many matrix-derived inhibitors of angiogenesis, such as endostatin, tumstatin, canstatin and arresten, are bioactive fragments of larger ECM molecules. These substances become released upon proteolysis of the ECM and the vascular basement membrane (VBM) by enzymes of the tumor microenvironment. Although the role of matrix-derived angiogenesis inhibitors is well studied in animal models of cancer, their role in human cancers is less established. In this review we discuss the current knowledge about these molecules and their potential use as cancer therapeutics and biomarkers. View Full-Text
Keywords: angiogenesis; extracellular matrix; collagen; cancer; therapy; biomarker angiogenesis; extracellular matrix; collagen; cancer; therapy; biomarker
Show Figures

Graphical abstract

MDPI and ACS Style

Sund, M.; Nyberg, P.; Eikesdal, H.P. Endogenous Matrix-Derived Inhibitors of Angiogenesis. Pharmaceuticals 2010, 3, 3021-3039.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop